ArticlePloS one2017

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.

Shu-Fu Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.